Z
Zentalis Pharmaceuticals, Inc. (ZNTL)
NGM – Real Time Price. Currency in USD
4.28
+0.14 (3.38%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.28
+0.14 (3.38%)
At close: May 12, 2026, 4:00 PM EDT
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
| Name | Position |
|---|---|
| Mr. Haibo Wang | Chief Business Officer |
| Mr. Henry Gu | Senior VP & Head of Intellectual Property |
| Mr. Rajesh Israni | Executive VP of Regulatory Affairs & Medical Writing |
| Ms. Julie M. Eastland M.B.A. | CEO, President & Director |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | zntl-20260505.htm |
| 2026-04-30 | DEF 14A | zntl-20260429.htm |
| 2026-04-17 | 8-K | zntl-20260417.htm |
| 2026-04-09 | 8-K | zntl-20260409.htm |
| 2026-03-26 | 10-K | zntl-20251231.htm |
| 2026-01-09 | 8-K | zntl-20260106.htm |
| 2025-12-15 | 8-K | zntl-20251215.htm |
| 2025-11-10 | 10-Q | zntl-20250930.htm |
| 2025-08-26 | 8-K | zntl-20250826.htm |
| 2025-08-06 | 8-K | zntl-20250806.htm |